#melanoma

2 stories

#merck #moderna #ascon 2026 #biontech #bntx #business #cancer vaccine #european society for medical oncology #finance #ibb #intismeran autogene #nasdaq:mrna

Moderna Stock Rises 6% on Cancer Vaccine Data
Moderna stock climbs 6% after melanoma vaccine data shows 49% lower recurrence risk.
Yahoo Finance · 2m
Moderna Jumps 9% After Melanoma Data Wins Prestigious Slot
Moderna stock surges 9% as Phase 3 melanoma trial data secures top presentation slot at major cancer conference
24/7 Wall St. · 1m